Stimulation med 0,3 mg rekombinant human thyrotropin öger effekten af 131 I-behandling hos patienter med atoksisk nodulaer struma. En prospektiv, randomiseret, dobbeltblindet
undersögelse - sekundaerpublikation
Engelsk titel: Stimulation with 0,3 mg recombinant human thyrotropin (rhTSH) increases the effect of 131 I therapy in patients with nontoxic nodular goiter. A prospective, randomized, double-blind trial -
secondary publication
Läs online
Författare:
Egsgaard Nielsen V
;
Bonnema SJ
;
Boel-Jörgensen H
;
Gryupe P
;
Hegedus L
Email: viveque.egsgaard@ouh.fyns-amt.dk
Språk: Dan
Antal referenser: 9
Dokumenttyp:
RCT
UI-nummer: 06111381
Sammanfattning
Stimulation with 0,3 mg recombinant human thyrotropin (rhTSH) increases the effect of 131 I therapy in patients with nontoxic nodular goiter. A prospective, randomized, double-blind trial - Secondary publication Ugeskr Læger 2006;168(47):4098-4101 In a randomized, double-blind, placebo-controlled trial, 57 patients with nontoxic nodular goiter were stimulated with either 0.3 mg recombinant human thyrotropin (rhTSH) or placebo before radioactive iodine (131 I) therapy. After one year the goiter reduction had improved by 35% compared to conventional 131 I therapy. The difference was most pronounced in patients with a large goiter. Adverse effects, including development of permanent hypothyroidism, were significantly more frequent in the rhTSH group. Patient satisfaction was high and uninfluenced by the use of rhTSH.